2004
Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025
Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J. Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 35: 138-143. PMID: 14722445, PMCID: PMC2753236, DOI: 10.1097/00126334-200402010-00006.Peer-Reviewed Original ResearchConceptsChris Hani Baragwanath HospitalPrevention of motherHIV Type 1Solution of chlorhexidineConcentrations of chlorhexidineChild transmissionBaragwanath HospitalMaternal symptomsPrevention trialsThird trimesterClinical indicationsMaternity unitsSubjective complaintsVaginal areaWash groupType 1ChlorhexidineInfant examinationWomenSustainable interventionsTolerable concentrationInterventionMothersWashDifferent concentrations
1992
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxis